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BACKGROUnD
In this opinion paper, we provide scientific-based reasons about the huge therapeutic potential of 
adenosine A2A receptor antagonists, and about the huge challenges to demonstrate efficacy in clinical 
trials, i.e., to provide data now required to approve a new medication by the regulatory bodies, such 
as U.S. Food and Drug Administration (FDA).
Adenosine is an autacoid present in all tissue and body fluids. Adenosine, whose extracellular 
concentration is controlled by producing/degrading enzymes and by nucleoside transporters, acts 
via four (A1, A2A, A2B, and A3) specific cell surface receptors that belong to the superfamily of 
G-protein-coupled receptors. For decades, adenosine receptors have shown promise as targets 
of medications for a variety of ailments. Until recently, however, the only approved medicine 
was adenosine itself, i.e., the endogenous agonist, to combat arrhythmias, such as paroxysmal 
supraventricular tachycardia (1–3). Prospects are changing as the first medication targeting selec-
tively the adenosine A2A receptor has been approved few years ago in Japan. The recently approved 
drug is an antagonist, i.e., a receptor blocker (see later). A2A receptor antagonists show promise 
in neuroprotection, although for Huntington’s or Niemann Pick’s diseases it is suggested that 
antagonists may be detrimental and/or there is controversy on which is the efficacious interven-
tion, i.e., receptor activation or blockade [see Ref. (4–9) and references therein].
pOTEnTiAL OF A2A RECEpTOR LiGAnDS in THE THERApY  
OF nEURODEGEnERATiVE DiSEASES
At present, not only the A2A receptor (A2AR) is at the center stage for increasing the therapeutic 
tools in a variety of clinical indications, but this opinion paper focuses on the A2AR antagonists, 
which shows promise in immune-mediated control of cancer progression (10–13), in atrial fibril-
lation (14, 15), and in fighting against neurodegenerative diseases (see later). It is relevant that 
virtually all the selective A2AR antagonists whose toxicity has been tested in animal models are very 
safe. Safety has been confirmed in the clinical trials performed using different structures [e.g., Ref. 
(16, 17)]. Istradefylline (KW-6002) is one of the most studied antagonists; it is safe and efficacious 
in Parkinson’s disease. Accordingly, it was approved in Japan in 2013 for adjunctive treatment of 
Parkinson’s patients (under the Nouriast™) (18–20). To our knowledge, up to five clinical trials 
with different antagonists were or are being undertaken (18, 21), but none of them has yet got the 
approval by the U.S. FDA. In our opinion, the two main reasons of the difficulties in translating 
very promising preclinical assays into medications are (i) the tight requirements and (ii) the urgent 
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need of efficacious approaches to assess neurodegeneration/
neuroprotection in humans. It is commented in drug discovery 
forums that quite a number of current drugs could not pass today 
the tight requirements posed by the regulatory bodies. The issue 
of assessing how to measure the neuroprotective efficacy of a 
drug is commented later.
Parkinson’s and Alzheimer’s are the most extended neuro-
degenerative diseases in modern societies with high life expec-
tancy (22, 23). With some exceptions of early-onset symptoms 
(24), age is the main factor for triggering the clinical symptoms 
(25–28). Whereas, Parkinson’s disease patients have successful 
dopamine-replacement therapies and other tools that may be 
used in the disease progression or to decrease the appearance 
of the medication side effects (29–31), Alzheimer’s disease 
patients have not yet got any really efficacious therapeutic 
drug/tool (32, 33).
Clinical manifestation of Parkinson’s disease occurs when 
a significant number of nigral dopamine-producing neurons 
have disappeared. Natural aging leads to 18% of loss of tyrosine 
hydroxylase-positive neurons in the nigra, whereas the degree 
of denervation in patients is very wide, going from 50 to 90%, 
even shortly after diagnosis (34). In this study in post-mortem 
samples, the authors state: “with several of the short-duration 
subjects showing comparable, severe loss of tyrosine hydroxylase-
positive neurons to that seen in subjects 20 years, post-diagnosis” 
(34). The idea behind the use of A2AR antagonists in this disease 
is the adenosine-dopamine antagonism (35–37) in the striatum, 
where the expression of A2ARs is highest in the whole mamma-
lian body (38). Therefore, dopamine-replacement therapy may 
be potentiated by the blockade of the A2AR. Indeed, Nouriast™ 
may serve to achieve efficacy of dopamine-replacement therapies 
at lower levels of dopaminergic drugs, such as levodopa. But 
the key point is that whereas levodopa is not neuroprotective, 
several preclinical assays indicate that A2AR antagonists show 
neuroprotective effects [see Ref. (39–42)]. Moreover, transgenic 
A2AR animals are more resistant to neurodegeneration induced by 
either 1-methyl-4-phenyl-1,2,3,6 tetra-hydropyridine (MPTP)-
induced nigral lesion or focal cerebral ischemia (43–46). Further 
to those preclinical results, epidemiological studies showed that 
caffeine, which is a mixed/non-selective adenosine receptor 
antagonist, decrease the risk of suffering from Parkinson’s or 
from Alzheimer’s diseases [(47, 48); see Ref. (49) and references 
therein for review]. In summary, one challenge for the progres-
sion of A2AR antagonist into approved drugs is to demonstrate 
neuroprotection in humans, for instance to decrease the death 
rate of nigral dopaminergic neurons.
CHALLEnGES in DEVELOpinG 
nEUROpROTECTiVE MEDiCinES
Based on development of our profession of translational research 
we notice that, often, scientific reports do not distinguish among 
symptom improvement and disease modifying drugs. Any drug 
that “improves” the condition of a parkinsonian animal model 
may be considered as neuroprotective. When the drug faces a 
clinical trial with patients, the promoter has to decide between 
analyzing symptom improvement and disease progression as 
primary outcome measure. For reasons further specified below, 
clinical trials for common neurodegenerative diseases analyze 
symptoms as primary outcome with a further difficulty: for 
ethical reasons patients should continue to take the ad  hoc 
medication. Therefore, it is difficult to address whether any new 
medicine is improving symptoms or decreasing the side effects. 
For instance, parkinsonian patients recruited for clinical trials 
continue taking levodopa; thus, the assayed new drug must 
improve symptoms or reduce side effects appearing after years 
of taking levodopa. Difficulties in approving disease modifying, 
i.e., neuroprotective, medication for Parkinson’s were already 
noticed and reviewed years ago (50). Although the issue is on 
the table, to our knowledge there is not any effective action for 
neurodegenerative diseases unlike the case of rare diseases for 
which drug approval may be accelerated. There is an apparent 
lack of consensual rules to evaluate, and consequently approve, 
drugs whose action is to prevent neuronal death, i.e., drugs 
that modify the progression of a neurodegenerative disease. 
Apart from hoping for specific measures tackling this issue at 
the regulatory level, we think that (i) we are quickly moving to 
have reliable neuroprotection biomarkers with positron emis-
sion tomography resolution, i.e., to monitor neurodegeneration 
in vivo in humans and (ii) regulatory bodies should consider 
the approval of the use of safe drugs in healthy cohorts to 
assess the long-term potential as neuroprotectants (assump-
tion would be that drug should delay clinical symptoms and/or 
delay neurodegenerative disease progression). The latter may 
seem risky but, again in our opinion, not riskier than taking 
food supplements or drug supplements to “combat aging,” such 
as testosterone.
CHALLEnGES in DESiGninG 
nEUROpROTECTiVE A2AR AnTAGOniSTS
The two sides of drug action, i.e., addressing symptoms and dis-
ease progression, should be considered for any drug type (A2AR 
antagonists in this article). Whereas in the case of Parkinson’s 
disease, the targets of antagonists in adjunctive treatments of 
dopamine-replacement therapies are A2AR receptors in neu-
rons, the A2A receptor containing targeted cells in the MPTP 
model of Parkinson’s disease that could be responsible for the 
neuroprotective action could not be determined in transgenic 
animals with cell-type-specific (conditional) deletion of the 
receptor (46). In this scenario, and based in convergent and 
wide experimental evidence, we consider that the role of the A2A 
receptor expressed in microglia should not be neglected. Hence, 
another challenge is to select (for a given disease) the receptor to 
be targeted, but also the cell where the receptor must be targeted 
and/or when the receptor of a given cell (neuron or glia) must 
be targeted to afford neuroprotection. Years ago, we found a 
relevant A2AR-related side result on studying gene expression in 
samples from Alzheimer’s patients. Genomics-relevant results 
were upregulation in samples from patients of the Kv3.4 voltage-
gated potassium channel (51) and of the adenosine A1 receptor 
(52). Interestingly, when we moved to perform immunostaining 
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in the cerebral cortex and hippocampus from necropsies of 
Alzheimer’s disease (AD) patients, we confirmed the upregula-
tion of the adenosine A2A receptor concomitant with a change 
in the pattern of expression. The receptor was found inter alia 
in degenerating structures, i.e., in both dystrophic neurites and 
neurons exhibiting neurofibrillary tangles. Whereas, specific 
mRNA expression in the assayed brain areas was not different 
from that found in control samples, the microglial expression 
of the protein was negligible or absent in control samples but 
was evidently expressed in microglial cells in both the cerebral 
cortex and the hippocampus of patients (52).
Function of immune cells in the periphery and of microglia in 
the CNS is regulated by the A2AR. Due to the extensive work of M. 
Sitkovsky’s and other laboratories devoted to targeting adenosine 
receptors to combat cancer, the already promising immuno-
therapy to combat certain tumor types, may be enhanced by the 
blockade of A2AR expressed in immune cells (10–13). Provided 
that ATP is degraded to adenosine in oxygen partial deficiency 
and/or cell death occurring in degenerating environments, 
increased adenosine levels activate upregulated microglial A2ARs. 
Therefore, an obligate drug discovery approach is to target those 
cells and those receptors that promote M2-skewed microglial 
responses.
We highlight microglia as the most likely cell type to be targeted 
(for neuroprotection) by A2AR antagonists. Straightforward data 
in different models, support the view that A2AR activation in glia 
drives neuroinflammation and, therefore, the selective blockade 
of this receptor may be neuroprotective (40, 53–58). We think 
that more experimental effort is required to define when and 
how A2AR antagonists may achieve conversion from M1-skewed 
(proinflammatory) to M2-skewed (neuroprotective) microglia, 
something that requires control of the production of cytokines/
chemokines, interferon-gamma, etc. [see (59) for review]. 
Intrinsic to any transformation, in this case into M1 or into M2 
cells, there is a time window of opportunity whose starting point 
and duration should be also explored. In other words, when to 
start the application of the intervention and when it is too late.
We would like to end this paper with a further opinion, which 
A2AR antagonists may “conceptually” be the new beta-blockers 
(ß-adrenergic antagonists) whose therapeutic potential is vast 
from cardiovascular problems to asthma.
AUTHOR COnTRiBUTiOnS
The two authors participated in the conceptual design of this 
opinion article. RF did literature search. The two authors 
contributed to the writing and carefully checked English 
spelling/grammar.
FUnDinG
Partially supported by grant BFU-2015-64405-R from Spanish 
Ministry of Economy and Competitiveness (may include EU 
FEDER funds).
REFEREnCES
1. Bailey AM, Baum RA, Rose J, Humphries RL. High-dose adenosine for treat-
ment of refractory supraventricular tachycardia in an emergency department 
of an academic medical center: a case report and literature review. J Emerg 
Med (2016) 50:477–81. doi:10.1016/j.jemermed.2015.11.012 
2. DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, et  al. 
Adenosine for paroxysmal supraventricular tachycardia: dose ranging and 
comparison with verapamil. Assessment in placebo-controlled, multicenter 
trials. The adenosine for PSVT Study Group. Ann Intern Med (1990) 113: 
104–10. doi:10.7326/0003-4819-113-2-104 
3. Lerman BB. Mechanism, diagnosis, and treatment of outflow tract tachycar-
dia. Nat Rev Cardiol (2015) 12:597–608. doi:10.1038/nrcardio.2015.121 
4. Chiu F-LL, Lin J-TT, Chuang C-YY, Chien T, Chen C-MM, Chen K-HH, et al. 
Elucidating the role of the A2A adenosine receptor in neurodegeneration 
using neurons derived from Huntington’s disease iPSCs. Hum Mol Genet 
(2015) 24:6066–79. doi:10.1093/hmg/ddv318 
5. Lee C, Chern Y. Adenosine receptors and Huntington’s disease. Int Rev 
Neurobiol (2014) 119:195–232. doi:10.1016/B978-0-12-801022-8.00010-6 
6. Leiva A, Guzmán-Gutiérrez E, Contreras-Duarte S, Fuenzalida B, Cantin C, 
Carvajal L, et  al. Adenosine receptors: modulators of lipid availability that 
are controlled by lipid levels. Mol Aspects Med (2017) 55:26–44. doi:10.1016/j.
mam.2017.01.007 
7. Li W, Silva HB, Real J, Wang Y-M, Rial D, Li P, et  al. Inactivation of ade-
nosine A2A receptors reverses working memory deficits at early stages of 
Huntington’s disease models. Neurobiol Dis (2015) 79:70–80. doi:10.1016/j.
nbd.2015.03.030 
8. Popoli P, Blum D, Domenici MR, Burnouf S, Chern Y. A critical evaluation 
of adenosine A2A receptors as potentially “druggable” targets in Huntington’s 
disease. Curr Pharm Des (2008) 14:1500–11. doi:10.2174/138161208784480117 
9. Tyebji S, Saavedra A, Canas PM, Pliassova A, Delgado-García JM, 
Alberch J, et  al. Hyperactivation of D1 and A2A receptors contributes to 
cognitive dysfunction in Huntington’s disease. Neurobiol Dis (2015) 74:41–57. 
doi:10.1016/j.nbd.2014.11.004 
10. Hatfield SM, Sitkovsky M. A2A adenosine receptor antagonists to weaken 
the hypoxia-HIF-1α driven immunosuppression and improve immunother-
apies of cancer. Curr Opin Pharmacol (2016) 29:90–6. doi:10.1016/j.coph. 
2016.06.009 
11. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The 
development and immunosuppressive functions of CD4+ CD25+ FoxP3+ 
regulatory T cells are under influence of the adenosine-A2A adenosine recep-
tor pathway. Front Immunol (2012) 3:190. doi:10.3389/fimmu.2012.00190 
12. Ohta A, Sitkovsky M. Methylxanthines, inflammation, and cancer: 
fundamental mechanisms. Handb Exp Pharmacol (2011) 200:469–81. 
doi:10.1007/978-3-642-13443-2_19 
13. Sitkovsky MV, Hatfield S, Abbott R, Belikoff B, Lukashev D, Ohta A. 
Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to 
overcome for tumor immunologists. Cancer Immunol Res (2014) 2:598–605. 
doi:10.1158/2326-6066.CIR-14-0075 
14. Hove-Madsen L, Prat-Vidal C, Llach A, Ciruela F, Casadó V, Lluis C, et al. 
Adenosine A2A receptors are expressed in human atrial myocytes and mod-
ulate spontaneous sarcoplasmic reticulum calcium release. Cardiovasc Res 
(2006) 72:292–302. doi:10.1016/j.cardiores.2006.07.020 
15. Llach A, Molina CE, Prat-Vidal C, Fernandes J, Casado V, Ciruela F, et  al. 
Abnormal calcium handling in atrial fibrillation is linked to up-regulation 
of adenosine A 2A receptors. Eur Heart J (2011) 32:721–9. doi:10.1093/
eurheartj/ehq464 
16. Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, 
et  al. Tozadenant (SYN115) in patients with Parkinson’s disease who have 
motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. 
Lancet Neurol (2014) 13:767–76. doi:10.1016/S1474-4422(14)70148-6 
17. Mizuno Y, Kondo T. Adenosine A2A receptor antagonist istradefylline 
reduces daily OFF time in Parkinson’s disease. Mov Disord (2013) 28:1138–41. 
doi:10.1002/mds.25418 
4Franco and Navarro Adenosine Receptor Antagonists and Neuroprotection
Frontiers in Psychiatry | www.frontiersin.org March 2018 | Volume 9 | Article 68
18. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, 
adenosine A 2A antagonists, and Parkinson’s disease. Parkinsonism Relat 
Disord (2009) 15:406–13. doi:10.1016/j.parkreldis.2008.12.006 
19. Kondo T, Mizuno Y, Japanese Istradefylline Study Group. A long-term study 
of istradefylline safety and efficacy in patients with Parkinson disease. Clin 
Neuropharmacol (2015) 38:41–6. doi:10.1097/WNF.0000000000000073 
20. Navarro G, Borroto-Escuela DODO, Fuxe K, Franco R. Purinergic signaling 
in Parkinson’s disease. Relevance for treatment. Neuropharmacology (2015) 
104:161–8. doi:10.1016/j.neuropharm.2015.07.024 
21. Jenner P. An overview of adenosine A2A receptor antagonists in Parkinson’s 
disease. Int Rev Neurobiol (2014) 119:71–86. doi:10.1016/B978-0-12-801022- 
8.00003-9 
22. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, et al. Time to 
redefine PD? Introductory statement of the MDS task force on the defi-
nition of Parkinson’s disease. Mov Disord (2014) 29:454–62. doi:10.1002/
mds.25844 
23. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk 
factors and biomarkers. Biochem Pharmacol (2014) 88:640–51. doi:10.1016/j.
bcp.2013.12.024 
24. Calderón-Garcidueñas L, Franco-Lira M, Mora-Tiscareño A, Medina-
Cortina H, Torres-Jardón R, Kavanaugh M. Early Alzheimer’s and Parkinson’s 
disease pathology in Urban children: friend versus Foe responses—it is 
time to face the evidence. Biomed Res Int (2013) 2013:1–16. doi:10.1155/ 
2013/161687 
25. Adalbert R, Coleman MP. Review: axon pathology in age-related neuro-
degenerative disorders. Neuropathol Appl Neurobiol (2013) 39:90–108. 
doi:10.1111/j.1365-2990.2012.01308.x 
26. Calabrese V, Santoro A, Monti D, Crupi R, Di Paola R, Latteri S, et  al.  
Aging and Parkinson’s disease: inflammaging, neuroinflammation and bio-
logical remodeling as key factors in pathogenesis. Free Radic Biol Med (2018) 
115:80–91. doi:10.1016/j.freeradbiomed.2017.10.379 
27. Coria F, Rubio I, Bayon C. Alzheimer’s disease, beta-amyloidosis, and aging. 
Rev Neurosci (1994) 5:275–92. doi:10.1515/REVNEURO.1994.5.4.275 
28. Tanzi RE. A genetic dichotomy model for the inheritance of Alzheimer’s 
disease and common age-related disorders. J Clin Invest (1999) 104:1175–9. 
doi:10.1172/JCI8593 
29. Birkmayer W, Hornykiewicz O. Additional experimental studies on L-DOPA 
in Parkinson’s syndrome and reserpine parkinsonism. Arch Psychiatr Ner-
venkr (1964) 206:367–81. doi:10.1007/BF00341704 
30. Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian 
brain. J Neural Transm Suppl (2006) 70:9–15. doi:10.1007/978-3-211- 
45295-0_3 
31. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, et al. 
Levodopa in the treatment of Parkinson’s disease: current controversies. Mov 
Disord (2004) 19:997–1005. doi:10.1002/mds.20243 
32. Féger J, Hirsch EC. In search of innovative therapeutics for neuropsychiatric 
disorders: the case of neurodegenerative diseases. Ann Pharm Fr (2015) 
73:3–12. doi:10.1016/j.pharma.2014.10.001 
33. Franco R, Cedazo-Minguez A. Successful therapies for Alzheimer’s disease: 
why so many in animal models and none in humans? Front Pharmacol (2014) 
5:146. doi:10.3389/fphar.2014.00146 
34. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. 
Disease duration and the integrity of the nigrostriatal system in Parkinson’s 
disease. Brain (2013) 136:2419–31. doi:10.1093/brain/awt192 
35. Fuxe K, Strömberg I, Popoli P, Rimondini-Giorgini R, Torvinen M, Ogren SO, 
et al. Adenosine receptors and Parkinson’s disease. Relevance of antagonistic 
adenosine and dopamine receptor interactions in the striatum. Adv Neurol 
(2001) 86:345–53. 
36. Josselyn SA, Beninger RJ. Behavioral effects of intrastriatal caffeine mediated 
by adenosinergic modulation of dopamine. Pharmacol Biochem Behav (1991) 
39:97–103. doi:10.1016/0091-3057(91)90403-O 
37. Wood PL, Kim HS, Boyar WC, Hutchison A. Inhibition of nigrostriatal release 
of dopamine in the rat by adenosine receptor agonists: A1 receptor mediation. 
Neuropharmacology (1989) 28:21–5. doi:10.1016/0028-3908(89)90062-2 
38. Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. Immunohisto-
chemical localization of adenosine A 2A receptors in the rat central ner vous 
system. J Comp Neurol (1998) 401:163–86. doi:10.1002/(SICI)1096-9861 
(19981116)401 
39. Chen J-F, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, et  al. 
Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, 
multifaceted actions and “fine tuning” modulation. Prog Neurobiol (2007) 
83:310–31. doi:10.1016/j.pneurobio.2007.09.002 
40. Chen J-F, Pedata F. Modulation of ischemic brain injury and neuroinflam-
mation by adenosine A2A receptors. Curr Pharm Des (2008) 14:1490–9. 
doi:10.2174/138161208784480126 
41. Sebastião AM, Ribeiro JA. Triggering neurotrophic factor actions through 
adenosine A2A receptor activation: implications for neuroprotection. Br 
J Phar macol (2009) 158:15–22. doi:10.1111/j.1476-5381.2009.00157.x 
42. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological 
disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 
(2009) 193:535–87. doi:10.1007/978-3-540-89615-9_17 
43. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, et al. A2A adenosine 
receptor deficiency attenuates brain injury induced by transient focal ischemia 
in mice. J Neurosci (1999) 19:9192–200. 
44. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, et al. Neuroprotection by 
caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s 
disease. J Neurosci (2001) 21:RC143. 
45. Gui L, Duan W, Tian H, Li C, Zhu J, Chen J-F, et al. Adenosine A2A receptor 
deficiency reduces striatal glutamate outflow and attenuates brain injury 
induced by transient focal cerebral ischemia in mice. Brain Res (2009) 
1297:185–93. doi:10.1016/j.brainres.2009.08.050 
46. Xu K, Di Luca DG, Orrú M, Xu Y, Chen J-F, Schwarzschild MA. Neuroprotection 
by caffeine in the MPTP model of Parkinson’s disease and its dependence on 
adenosine A 2A receptors. Neuroscience (2016) 322:129–37. doi:10.1016/j.
neuroscience.2016.02.035 
47. Ross G, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, 
et  al. Association of coffee and caffeine intake with the risk of Parkinson 
disease. JAMA (2000) 283:2674–9. doi:10.1001/jama.283.20.2674 
48. Maia L, de Mendonça A. Does caffeine intake protect from Alzheimer’s 
disease? Eur J Neurol (2002) 9:377–82. doi:10.1046/j.1468-1331.2002.00421.x 
49. Oñatibia-Astibia A, Franco R, Martínez-Pinilla E. Health benefits of methylx-
anthines in neurodegenerative diseases. Mol Nutr Food Res (2017) 61:1600670. 
doi:10.1002/mnfr.201600670 
50. Olanow CW, Kieburtz K, Schapira AHV. Why have we failed to achieve 
neuroprotection in Parkinson’s disease? Ann Neurol (2008) 64:S101–10. 
doi:10.1002/ana.21461 
51. Angulo E, Noé V, Casadó V, Mallol J, Gomez-Isla T, Lluis C, et al. Up-regulation 
of the Kv3.4 potassium channel subunit in early stages of Alzheimer’s 
disease. J Neurochem (2004) 91:547–57. doi:10.1111/j.1471-4159.2004. 
02771.x 
52. Angulo E, Casadó V, Mallol J, Canela EI, Viñals F, Ferrer I, et  al. A1 ade-
nosine receptors accumulate in neurodegenerative structures in Alzheimer 
disease and mediate both amyloid precursor protein processing and 
tau phosphorylation and translocation. Brain Pathol (2003) 13:440–51. 
doi:10.1111/j.1750-3639.2003.tb00475.x 
53. Abbracchio MP, Cattabeni F. Brain adenosine receptors as targets for thera-
peutic intervention in neurodegenerative diseases. Ann N Y Acad Sci (1999) 
890:79–92. doi:10.1111/j.1749-6632.1999.tb07983.x 
54. Brambilla R, Cottini L, Fumagalli M, Ceruti S, Abbracchio MP. Blockade of 
A2A adenosine receptors prevents basic fibroblast growth factor-induced 
reactive astrogliosis in rat striatal primary astrocytes. Glia (2003) 43:190–4. 
doi:10.1002/glia.10243 
55. Gyoneva S, Shapiro L, Lazo C, Garnier-Amblard E, Smith Y, Miller GW, 
et  al. Adenosine A2A receptor antagonism reverses inflammation-induced 
impairment of microglial process extension in a model of Parkinson’s disease. 
Neurobiol Dis (2014) 67:191–202. doi:10.1016/j.nbd.2014.03.004 
56. Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K, et al. 
Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxy-
genase-2 expression, glial activation, and brain-derived neurotrophic factor 
availability in a rat model of striatal neurodegeneration. J Neuropathol Exp 
Neurol (2007) 66:363–71. doi:10.1097/nen.0b013e3180517477 
57. Nobre HV, de Andrade Cunha GM, de Vasconcelos LM, Magalhães HIF, 
Neto RNO, Maia FD, et al. Caffeine and CSC, adenosine A2A antagonists, offer 
neuroprotection against 6-OHDA-induced neurotoxicity in rat mesence-
pha lic cells. Neurochem Int (2010) 56:51–8. doi:10.1016/j.neuint.2009. 
09.001 
58. Saura J, Angulo E, Ejarque A, Casado V, Tusell JM, Moratalla R, et  al. 
Adenosine A2A receptor stimulation potentiates nitric oxide release by acti-
vated microglia. J Neurochem (2005) 95:919–29. doi:10.1111/j.1471-4159. 
2005.03395.x 
5Franco and Navarro Adenosine Receptor Antagonists and Neuroprotection
Frontiers in Psychiatry | www.frontiersin.org March 2018 | Volume 9 | Article 68
59. Franco R, Fernández-Suárez D. Alternatively activated microglia and mac-
rophages in the central nervous system. Prog Neurobiol (2015) 131:65–86. 
doi:10.1016/j.pneurobio.2015.05.003 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Franco and Navarro. This is an open-access article distrib-
uted under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) and the copyright owner are credited and that the original 
publication in this journal is cited, in accordance with accepted academic prac-
tice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
